CyberKnife Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy As First-line Treatments for Imaging-diagnosed Intracranial Meningiomas
| العنوان: | CyberKnife Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy As First-line Treatments for Imaging-diagnosed Intracranial Meningiomas |
|---|---|
| المؤلفون: | Takeshi Tamura, Hiroyuki Ogino, M. Iwabuchi, Yuta Shibamoto, Taro Murai, Hirochika Suzuki, Yoshihiko Manabe, Yoshimasa Mori, Hiromitsu Iwata |
| المصدر: | Neurologia medico-chirurgica |
| بيانات النشر: | Japan Neurosurgical Society, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_treatment, First line, stereotactic radiosurgery, CyberKnife, Radiosurgery, meningioma, Disease-Free Survival, Stereotactic radiotherapy, Meningioma, 03 medical and health sciences, 0302 clinical medicine, Cyberknife, hypofractionated stereotactic radiotherapy, Meningeal Neoplasms, medicine, Humans, Survival rate, Definitive radiotherapy, Aged, Retrospective Studies, Aged, 80 and over, medicine.diagnostic_test, Brain Neoplasms, business.industry, Magnetic resonance imaging, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Treatment Outcome, 030220 oncology & carcinogenesis, Original Article, stereotactic radiotherapy, Female, Surgery, Dose Fractionation, Radiation, Neurology (clinical), Tomography, X-Ray Computed, business, Nuclear medicine, 030217 neurology & neurosurgery |
| الوصف: | Definitive radiotherapy is an important alternative treatment for meningioma patients who are inoperable or refuse surgery. We evaluated the efficacy and toxicity of CyberKnife-based stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (hSRT) as first-line treatments for intracranial meningiomas that were diagnosed using magnetic resonance imaging (MRI) and/or computed tomography (CT). Between February 2005 and September 2015, 41 patients with intracranial meningiomas were treated with CyberKnife-based SRS or hSRT. Eleven of those tumors were located in the skull base. The median tumor volume was 10.4 ml (range, 1.4–56.9 ml). The median prescribed radiation dose was 17 Gy (range, 13–20 Gy to the 61–88% isodose line) for SRS (n = 9) and 25 Gy (range, 14–38 Gy to the 44–83% isodose line) for hSRT (n = 32). The hSRT doses were delivered in 2 to 10 daily fractions. The median follow-up period was 49 months (range, 7–138). The 5-year progression-free survival rate (PFS) for all 41 patients was 86%. The 3-year PFS was 69% for the 14 patients with tumor volumes of ≥13.5 ml (30 mm in diameter) and 100% for the 27 patients with tumor volumes of 2 toxicities were observed in 5 patients (all of them had tumor volumes of ≥13.5 ml). SRS and hSRT are safe and effective against relatively small ( |
| تدمد: | 1349-8029 0470-8105 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32cd14c0e53fc110cc0379a64ed5a6ffTest https://doi.org/10.2176/nmc.oa.2017-0115Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....32cd14c0e53fc110cc0379a64ed5a6ff |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13498029 04708105 |
|---|